Get the Stockscreener App
2.29
25.82%
0.47
After Hours:
2.27
-0.02
-0.87%
Neumora Therapeutics Inc stock is traded at $2.29, with a volume of 13.52M.
It is up +25.82% in the last 24 hours and up +3.15% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$1.82
Open:
$2.08
24h Volume:
13.52M
Relative Volume:
6.96
Market Cap:
$389.16M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.9035
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
+27.93%
1M Performance:
+3.15%
6M Performance:
+155.78%
1Y Performance:
-11.24%
1-Day Range:
$2.05
$2.54
1-Week Range:
$1.50
$2.54
52-Week Range:
$0.611
$3.25
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.29 | 309.29M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-27-25 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-16-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Mizuho reiterates Outperform rating on Neumora Therapeutics stock By Investing.com - Investing.com UK
Analysts Are Bullish on These Healthcare Stocks: Fortrea Holdings Inc. (FTRE), DENTSPLY SIRONA (XRAY) - The Globe and Mail
Neumora outlines 2026 pipeline milestones for neuroscience programs By Investing.com - Investing.com Nigeria
Neumora gains after early-stage trial results for Alzheimer’s product - MSN
Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target - TipRanks
Mizuho raises Neumora Therapeutics stock price target on positive trial data - Investing.com Canada
Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses - MarketBeat
Neumora shares climb after encouraging Phase 1b results for Alzheimer’s agitation therapy - MSN
Why Is Neumora Therapeutics Stock Gaining Monday?Neumora Therapeutics (NASDAQ:NMRA) - Benzinga
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug - Investing.com Canada
NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study - Nasdaq
Neumora outlines 2026 pipeline milestones for neuroscience programs - Investing.com
Neumora posts trial results for Alzheimer’s drug (NMRA:NASDAQ) - Seeking Alpha
Neumora reports promising Phase 1b results in Alzheimer’s agitation - TipRanks
Neumora Therapeutics Announces Positive Phase 1b Study Results for NMRA-511 - TradingView — Track All Markets
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - The Manila Times
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation - The Manila Times
New Alzheimer’s treatment candidate eases agitation in early study - Stock Titan
10 Best New Penny Stocks to Invest In - Insider Monkey
RBC Sees Upside Potential in Neumora Therapeutics (NMRA) - Finviz
What analysts say about Neumora Therapeutics Inc stockMid Cap Growth Trends & Free Superior Trading Gains - earlytimes.in
Neumora stock rises after positive Phase 1b data for Alzheimer’s agitation drug By Investing.com - Investing.com South Africa
Momentum Shift: Will Neumora Therapeutics Inc. stock benefit from AI adoptionNew Guidance & Consistent Income Trade Recommendations - moha.gov.vn
Cash Runway Looks Solid, But Is Neumora's Pipeline Ready To Deliver? - RTTNews
Is Neumora Therapeutics Inc. stock resilient to inflation2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Can Neumora Therapeutics Inc. stock beat market expectations this quarterQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - Улправда
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Analyst Calls: How Neumora Therapeutics Inc stock reacts to job market dataIPO Watch & Smart Swing Trading Techniques - moha.gov.vn
Is Neumora Therapeutics Inc. stock a defensive play in 2025July 2025 Pullbacks & AI Powered Market Entry Ideas - DonanımHaber
Will Neumora Therapeutics Inc. stock beat EPS estimates2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - DonanımHaber
Why Neumora Therapeutics Inc. stock could rally in 2025Stop Loss & Stock Portfolio Risk Management - Улправда
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Earnings Notes - Trefis
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
MACD Signal: Can Neumora Therapeutics Inc stock beat market expectations this quarterJuly 2025 Update & Verified Chart Pattern Signals - BỘ NỘI VỤ
Neumora Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset - MSN
Can Neumora Therapeutics Inc. stock weather global recession2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
How Neumora Therapeutics Inc. stock reacts to job market dataQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Is Neumora Therapeutics Inc. stock attractive for ETFsPortfolio Growth Summary & Technical Buy Zone Confirmation - Newser
What momentum indicators show for Neumora Therapeutics Inc. stockGold Moves & Safe Capital Investment Plans - Newser
Neumora Therapeutics (NMRA) Stock Analysis Report | Financials & Insights - Benzinga
Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential - Investing.com Canada
Neumora Therapeutics Shares Rise After RBC Upgrade - marketscreener.com
Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset (NMRA:NASDAQ) - Seeking Alpha
Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline - Benzinga
This Chevron Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
RBC Capital Upgrades Neumora Therapeutics (NMRA) - Nasdaq
RBC Upgrades Neumora Therapeutics to Outperform From Sector Perform, Raises Price Target to $7 From $4, Keeps Speculative Risk - marketscreener.com
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):